CAGRILINTIDE
Appetite & Weight Management Support
WHAT IT IS:
An amylin hormone-like peptide that works with your body’s natural hunger signals to reduce appetite and support healthy weight loss.
WHY YOU NEED IT:
Clinically Studied Mechanism for Appetite Regulation
Important for patients with overweight or obesity who have struggled with diet and exercise alone
Targets patients who do not want GLP-1 meds or have failed them
Supports patients who have plateaued on GLP-1 therapy (such as semaglutide —Ozempic, Wegovy— or tirzepatide—Mounjaro, Zepbound) and need additional appetite support
Good for patients with strong food cravings, frequent hunger, or difficulty feeling full at meals
Great for patients with metabolic concerns, including insulin resistance and pre-diabetes, who need comprehensive weight management
Supports patients who tolerate GLP-1 medications poorly and may benefit from a lower GLP-1 dose combined with an amylin analogue
Important for patients seeking a once-weekly protocol that fits a busy lifestyle
HOW IT HELPS:
Weight management is rarely just about willpower — it's about biology. The hormones that govern hunger, fullness, and how quickly your stomach empties are powerful drivers of how much you eat and how satisfied you feel.
Cagrilintide is designed to work directly with those hormonal signals to make healthy eating feel more natural and sustainable.
Cagrilintide is a modified form of amylin, a hormone your pancreas releases every time you eat. Natural amylin tells your brain you're full, slows the speed at which food leaves your stomach, and helps keep blood sugar steady after meals. Cagrilintide was created to last longer than the ‘short-acting’ amylin.
A Complementary Pathway to GLP-1 Medications
GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and terzepatide (Mounjaro, Zepbound) have transformed weight management by acting on one appetite pathway in the brain. Amylin analogues like Cagrilintide act on a different but complementary pathway — the amylin receptor system in regions of the brain that help regulate appetite and gastric emptying. Activating both pathways (GLP-1 and Amylin) at once has been shown in clinical studies to produce greater appetite suppression and greater weight loss than either pathway alone. This is why Cagrilintide is prescribed in combination with a GLP-1 medication — a protocol often referred to as COMBI therapy.
Enhanced Satiety and Reduced Cravings
By binding to amylin receptors in the brain, Cagrilintide supports the natural sensation of fullness, reduces food intake, and slows gastric motility… so meals feel more satisfying for longer. Many patients report a noticeable reduction in cravings, less preoccupation with food between meals, and greater ease in following a weight loss plan.
For patients who have felt that hunger and cravings were always working against them, this shift can be profound.
Metabolic Support
In addition to its effects on appetite and weight, amylin signaling plays a role in glucose regulation by helping moderate post-meal blood sugar spikes. This makes Cagrilintide particularly relevant for patients with Insulin Resistance, Pre-Diabetes, or Type 2 Diabetes who are pursuing weight loss as part of their overall metabolic health strategy.
Clinical Evidence
In a landmark Phase 2 trial published in The Lancet (Wharton et al., 2022), once-weekly cagrilintide produced dose-dependent weight loss in adults with overweight or obesity, and the combination of cagrilintide with semaglutide 2.4 mg weekly produced significantly greater weight loss than semaglutide alone. Novo Nordisk, the developer, has continued to study the combination (CagriSema) in large-scale clinical trials targeting both obesity and Type 2 Diabetes.
What to Expect
Dosing begins low and is titrated gradually over several weeks to allow your body to adapt and to minimize side effects. The most common side effects are gastrointestinal in nature — mild nausea, decreased appetite, occasional constipation, or delayed gastric emptying — and these typically ease over time as your body adjusts. Injection site reactions are usually minor. Steady-state levels are reached after several weekly doses, at which point patients often describe a noticeable and sustained shift in how they relate to food.
Who Should Not Use Cagrilintide
Cagrilintide is not appropriate for patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, a history of pancreatitis, severe gastrointestinal disease including gastroparesis, known hypersensitivity to amylin analogues, or for women who are pregnant or breastfeeding.
DOSAGE:
Starting Dose: 0.3 mg by subcutaneous injection, once weekly.
Titration: Dose is gradually increased over several weeks under physician supervision, up to a typical maintenance range of 2.4 mg to 4.5 mg once weekly, based on tolerance and clinical response.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.